David Dickason - RespireRx Pharmaceuticals VP Devel

RSPIDelisted Stock  USD 0.01  0.00  0.00%   

Insider

David Dickason is VP Devel of RespireRx Pharmaceuticals
Age 59
Phone201 444 4947
Webhttps://www.respirerx.com

RespireRx Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (8.3401) % which means that it has lost $8.3401 on every $100 spent on assets. This is way below average. RespireRx Pharmaceuticals' management efficiency ratios could be used to measure how well RespireRx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
RespireRx Pharmaceuticals currently holds 2.42 M in liabilities. RespireRx Pharmaceuticals has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist RespireRx Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, RespireRx Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like RespireRx Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RespireRx to invest in growth at high rates of return. When we think about RespireRx Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Ruud OutersterpPharming Group NV
59
Anurag RelanPharming Group NV
51
Jeroen WakkermanPharming Group NV
54
Stephen ToorPharming Group NV
52
Eric TseSino Biopharmaceutical Ltd
27
Robert MDProtagenic Therapeutics
74
Daniel RyweckSilo Pharma
59
Mireille MScPharming Group NV
55
MBA MDPharming Group NV
63
David HovlandEledon Pharmaceuticals
N/A
Jeffrey BornsteinEledon Pharmaceuticals
N/A
Gregory FlesherEledon Pharmaceuticals
54
Susanne EmbletonPharming Group NV
N/A
David LovejoyProtagenic Therapeutics
N/A
Andrew SleeProtagenic Therapeutics
75
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey. Respirerx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people. RespireRx Pharmaceuticals [RSPI] is a Pink Sheet which is traded between brokers as part of OTC trading. RespireRx Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

RespireRx Pharmaceuticals Leadership Team

Elected by the shareholders, the RespireRx Pharmaceuticals' board of directors comprises two types of representatives: RespireRx Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RespireRx. The board's role is to monitor RespireRx Pharmaceuticals' management team and ensure that shareholders' interests are well served. RespireRx Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RespireRx Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jeff Margolis, VP, Treasurer, Secretary and Director
Richard Purcell, Senior Vice President - Research and Development
Arvid Carlsson, Consultant
David Dickason, VP Devel
Arnold Lippa, Executive Chairman and Chief Scientific Officer
Marc Radin, Controller

RespireRx Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is RespireRx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Other Consideration for investing in RespireRx Pink Sheet

If you are still planning to invest in RespireRx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RespireRx Pharmaceuticals' history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Stocks Directory
Find actively traded stocks across global markets
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing